Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Published Online: 2025-08-?
Journal: Journal of Clinical OncologyLoading...
Authors: Alessandro Sanna•Ananya Guntur•Bin Liu•Catherine C. Coombs•Ching Ching Leow•Christine I. Chen•Denise Y. Wang•Francesc Bosch•George Follows•Jeff P. Sharman•John M. Burke•Katherine Bao•Lindsey E. Roeker•Livia Compte•Lugui Qiu•Marisa Hill•Matthias Ritgen•Norbert Grzasko•Paolo Ghia•Paul M. Barr•Ru Feng•Sebastian Grosicki•Shuhua Yi•Talha Munir•Vishalkumar Patel•Vu Minh Hua•Wojciech Jurczak•Zoltán Mátrai
